Survival in Patients With Metastatic Prostate Cancer Undergoing Radiotherapy: The Importance of Prostate-Specific Antigen-Based Stratification

Zijian Tian; Lingfeng Meng; Xin Wang; Xuan Wang; Tianming Ma; Miao Wang; Qiuzi Zhong; Yaqun Zhang; Ming Liu

doi:10.3389/fonc.2021.706236

Survival in Patients With Metastatic Prostate Cancer Undergoing Radiotherapy: The Importance of Prostate-Specific Antigen-Based Stratification

Front Oncol. 2021 Jun 10:11:706236. doi: 10.3389/fonc.2021.706236. eCollection 2021.

Authors

Zijian Tian^{1

2}, Lingfeng Meng^{1

2}, Xin Wang¹, Xuan Wang¹, Tianming Ma^{1

2}, Miao Wang^{1

2}, Qiuzi Zhong¹, Yaqun Zhang^{1

2}, Ming Liu^{1

2}

Affiliations

¹ Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
² Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.

Abstract

Objectives: To explore the effectiveness of radiotherapy in mPCa patients with different PSA stratifications based on the cancer database of a large population.

Background: Screening criteria for patients with metastatic prostate cancer, who are candidates for radiotherapy, are rarely reported.

Patients and methods: We identified 22,604 patients with metastatic prostate cancer in the Surveillance, Epidemiology, and End Results database and divided them into a radiotherapy group and a control group. Patients with metastatic prostate cancer were divided into subgroups according to their levels of prostate-specific antigen to evaluate the efficacy of radiotherapy. They were also divided into six subgroups according to their prostate-specific antigen levels. We used multivariate Cox analysis to evaluate overall survival and cancer-specific survival. After 1:1 propensity score matching, Kaplan-Meier analysis was used to explore the difference in overall survival and cancer-specific survival in the radiotherapy and control group.

Results: In all, 5,505 patients received radiotherapy, compared to 17,099 in the control group. In the multivariate Cox analysis, radiotherapy improved overall survival (hazard ratio [HR]: 0.730, 95% confidence interval [CI]: 0.636-0.838; P<0.001) and cancer-specific survival (HR: 0.764, 95% CI: 0.647-0.903; P=0.002) in patients with a PSA level of 4-10 ng/mL. Similar results were obtained by Kaplan-Meier analysis after 1:1 propensity score matching. In patients with prostate-specific antigen levels between 4-10 ng/mL, the overall survival (P<0.001) and cancer-specific survival (P<0.05) in the radiotherapy group was significantly better than those in the control group.

Conclusion: The result of this large population-based study shows that rigorous selection of appropriate metastatic prostate cancer patients for radiotherapy can benefit prognosis significantly. This can be the basis for future prospective trials.

Keywords: SEER; metastatic prostate cancer; prostate-specific antigen; radiotherapy; survival analysis.